ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,263.26
0.61%
US Tech 100
22,232.00
0.63%
Dow Jones
44,458.30
0.49%
Brent Oil
69.76
0.04%
Bitcoin
111,063.90
-0.20%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) News

INmune Bio Inc

INmune Bio Inc (INMB)

NASDAQ
2.36
0.04
(1.72%)
Closed July 09 4:00PM
15 min delayed - Upgrade to Realtime
2.33
-0.03
(-1.27%)
After Hours: 7:56PM
15 min delayed - Upgrade to Realtime

Professional-Grade Tools, for Individual Investors.

Premium

INMB News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
June 30 2025
INMB (1.72%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
June 30 2025
INMB (1.72%)

Form 8-K - Current report
Edgar (US Regulatory)
June 30 2025
INMB (1.72%)

Form 8-K - Current report
Edgar (US Regulatory)
June 26 2025
INMB (1.72%)

Form 8-K - Current report
Edgar (US Regulatory)
June 10 2025
INMB (1.72%)

Form 8-K - Current report
Edgar (US Regulatory)
May 14 2025
INMB (1.72%)

Form DEFR14A - Revised definitive proxy soliciting materials
Edgar (US Regulatory)
May 09 2025
INMB (1.72%)

Form 8-K - Current report
Edgar (US Regulatory)
May 08 2025
INMB (1.72%)

INMB Discussion

View Posts
jondoeuk jondoeuk 1 week ago
The trial missed its primary endpoint. The trial also missed its secondary endpoints. I doubt they will find a partner to advance it.
👍️0
tredenwater2 tredenwater2 1 week ago
Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.

On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!

Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!
👍️ 2
tschussmann1 tschussmann1 1 week ago
Every Alzheimer's trial fail makes me appreciate AVXL that much more...
👍️ 2
tschussmann1 tschussmann1 1 week ago
Yes indeed! Fortunately it was a small stake...not much effect on the portfolio.
👍️0
retireat40 retireat40 1 week ago
Looks like a terrible decision 
👍️0
tschussmann1 tschussmann1 2 weeks ago
The low 5's after the 20% share increase priced at 6.30 provided a nice entry point...and not long to wait to see it it was a good decision.
👍️ 2
murocman murocman 2 weeks ago
Happens all the time.  Not a surprise.
👍️0
retireat40 retireat40 2 weeks ago
$5's
👍️0
retireat40 retireat40 2 weeks ago
Then they dropped an offering at $6.30. What a shit move. 
👍️0
rbl100 rbl100 2 weeks ago
OFFERING - @ $6.30 per share.....
👍️0
tw0122 tw0122 2 weeks ago
$13s 
👍️0
GhosTraderX GhosTraderX 2 weeks ago
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
https://ih.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/96320079/inmune-bio-inc-to-announce-top-line-results-from
GhosT
👍️ 4
jondoeuk jondoeuk 3 weeks ago
An update https://www.globenewswire.com/news-release/2025/06/02/3091859/0/en/Syncromune-Inc-Presents-Positive-Results-from-SYNC-T-Therapy-SV-102-Phase-1-Metastatic-Prostate-Cancer-Trial-at-ASCO-2025.html

https://www.globenewswire.com/news-release/2025/05/30/3091053/0/en/Syncromune-Announces-First-Patient-Dosed-in-LEGION-100-Phase-2a-Trial-of-SYNC-T-Therapy-SV-102-for-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html
👍️0
jondoeuk jondoeuk 4 months ago
Apples to oranges, but this is the kind of data you want to see https://syncromune.com/wp-content/uploads/2024/04/SYNC-T-AACR-Website.pdf
👍️0
jondoeuk jondoeuk 4 months ago
So no scans, waterfall or swimmer plots! Doesn't look like there is any single-agent activity https://archive.fast-edgar.com/20250304/AD29K22CLM22K282222G22Y2M9BIZ2224272/ea023314201ex99-1_inmune.htm

Drugs with no single-agent activity rarely, if ever improve outcomes in randomised and controlled trials when used alone or in combination.
👍️0
MartinLutherKing MartinLutherKing 6 months ago
ELAB Partnership
👍️0
Monksdream Monksdream 7 months ago
INMB under $5
👍️0
Monksdream Monksdream 8 months ago
INMB new 52 week low
👍️0
tw0122 tw0122 8 months ago
Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell.Multi-year study published has implications for many CNS diseases including Alzheimer's.
👍️0
tw0122 tw0122 8 months ago
INMB 5.27 something brewing over here in some
👍️0
Monksdream Monksdream 10 months ago
INMB new 52 week low
👍️0
Monksdream Monksdream 1 year ago
INMB under $10
👍️0
jondoeuk jondoeuk 1 year ago
''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

Good luck to them in solid tumours!
👍️0
Monksdream Monksdream 2 years ago
INMB indeed it did
👍️0
DollarDan DollarDan 2 years ago
Starting to move up!
👍️0
jondoeuk jondoeuk 2 years ago
Did the trial in ovarian ever start?
👍️0
derkampfer derkampfer 2 years ago
Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

Two robust programs and each have multi-billion value potential based on TAM

Exciting times.

GLTA longs
👍️0
jondoeuk jondoeuk 2 years ago
Sure, it is early days in patients, but the data has yet to be https://ashpublications.org/blood/article/140/Supplement%201/4590/492304/In-Vivo-Generation-of-Memory-like-NK-Cells-for-the

Keep in mind that the ORR (focusing on R/R AML) is ~30-35% across multiple trials using adoptive transfer of non-engineered NK cells.
👍️0
dennisdave dennisdave 3 years ago
blocked
👍️0
conix conix 3 years ago
INMB chart....finally a reversal?

👍️0
conix conix 4 years ago
INMB Chart

👍️0
derkampfer derkampfer 4 years ago
XPro news also impressive. Data very.

“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
👍️0
derkampfer derkampfer 4 years ago
INKmune news was impressive. Albeit one patient dosed additional eight (8) in line. No toxicity. Ovarian cancer on deck.

https://finance.yahoo.com/news/inmune-bio-inc-announces-biomarker-200000970.html
👍️0
spartex spartex 4 years ago
Almost, $13 to $10 is a downward slope. but maybe over time things will be reversed??
👍️0
spartex spartex 4 years ago
Booooooom? More like, BurP! LOL. Still researching INMB
👍️0
derkampfer derkampfer 4 years ago
New run began today. Deeper dive Alzheimer’s drug they’re developing is phenomenal. Early studies some patients seeing reversed effects.

Unbelievable.
👍️0
Fress Fress 4 years ago
$INMB just ran from $2.00 to 30.00 congrats to the longs. what a beast of a stock.



*INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.



$PDSB CD8+ (killer) T-cells. T cell platform is next.


$INMB
👍️0
john sezso john sezso 5 years ago
I need a bigger rake to scoop up all this cash trade....
👍️0
john sezso john sezso 5 years ago
Still crickets here....
👍️0
john sezso john sezso 5 years ago
Good enough for Harry Reid it's good enough for me. I'm in for the 50's
👍️0
byrdiesoccer byrdiesoccer 5 years ago
They are speaking with Roth Capital right now
👍️0
akamaii akamaii 5 years ago
Shorts bring this to 8 I wanna buy
👍️0
l2 hunter l2 hunter 5 years ago
INMB CHART >>>> going in position before test $25 next days again. after $25 blue skies... $13-$15 range a gift imho think will run big next days

👍️0
starkd748 starkd748 5 years ago
Wow that public offering is peanuts ...Kaboom here tomorrow
👍️0
l2 hunter l2 hunter 5 years ago
INMB ready to test $24 high from last week next days.. strong technical setting now.
👍️0
l2 hunter l2 hunter 5 years ago
INMB NEWS OUT!!!!!!!!! BOOOOOOOOOOOOOOOOOOOOMMMMMMMMMMMMMMMMMMMMMMMM
👍️0
l2 hunter l2 hunter 5 years ago
INMB CHART >>> Strong setting for next big wave above $20 next week if News update drop imho >>>>>

👍️0
ClayTrader ClayTrader 5 years ago
* * $INMB Video Chart 07-14-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
dinogreeves dinogreeves 5 years ago
Looks like a strong close finally.
👍️0
$treet $inatra $treet $inatra 5 years ago
INMB monster pop https://finance.yahoo.com/news/inmune-bio-inc-announces-interim-201600548.html
👍️0

Your Recent History

NASDAQ
INMB
INmune Bio
Delayed Upgrade Clock
ADVFN
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads